Insomnia Severity Index (ISI)

Validated 7-Item Sleep Assessment — Quick & Evidence-Based

Clinically Validated 7 Items Only 🔒 100% Private
7 Items Quick Assessment
30% Adults with Insomnia Symptoms
Score 0-28 4 Severity Levels
🔒 Your Privacy: All responses are processed entirely in your browser. No data is stored on our servers or shared with anyone. Your answers remain completely private.

Insomnia Severity Index Questionnaire

Please rate the current (i.e., last 2 weeks) severity of your insomnia problem(s).

1. Difficulty falling asleep

2. Difficulty staying asleep

3. Problems waking up too early

4. How satisfied/dissatisfied are you with your current sleep pattern?

5. How noticeable to others do you think your sleep problem is in terms of impairing the quality of your life?

6. How worried/distressed are you about your current sleep problem?

7. To what extent do you consider your sleep problem to INTERFERE with your daily functioning (e.g., daytime fatigue, mood, ability to function at work/daily chores, concentration, memory, mood, etc.) currently?

Understanding Insomnia

Insomnia is the most common sleep disorder, affecting approximately 30% of adults with occasional symptoms and 10% meeting criteria for chronic insomnia disorder. It is characterized by difficulty initiating sleep, maintaining sleep, or waking up too early, accompanied by daytime impairment.

Types of insomnia:

  • Sleep-onset insomnia: Difficulty falling asleep at the beginning of the night. Typically defined as taking more than 30 minutes to fall asleep. Often associated with anxiety, racing thoughts, or hyperarousal at bedtime.
  • Sleep-maintenance insomnia: Difficulty staying asleep through the night, with frequent or prolonged awakenings. This is the most common type in older adults and is often associated with pain, medical conditions, or mood disorders.
  • Early-morning awakening insomnia: Waking up significantly earlier than desired and being unable to return to sleep. Often associated with depression and advancing circadian rhythm changes with age.
  • Mixed insomnia: Many individuals experience a combination of these types, and the presentation may shift over time.

Acute vs. chronic insomnia:

  • Acute (short-term) insomnia: Lasts less than 3 months and is usually triggered by an identifiable stressor such as a life event, illness, travel, or environmental change. Often resolves on its own when the stressor is removed.
  • Chronic insomnia: Occurs at least 3 nights per week for 3 months or longer. It often develops when acute insomnia is perpetuated by maladaptive behaviors (e.g., spending excessive time in bed, napping, worrying about sleep). This is the primary target for clinical intervention.

Prevalence and impact: Insomnia is associated with increased risk of depression, anxiety, cardiovascular disease, diabetes, and impaired immune function. It is also linked to reduced work productivity, increased healthcare utilization, and higher accident rates. Women are approximately 1.5 times more likely than men to experience insomnia, and prevalence increases with age.

ISI Scoring and Clinical Use

The Insomnia Severity Index (ISI) was developed by Charles M. Morin in 1993 as a brief, reliable, and valid measure of insomnia severity. It assesses seven dimensions of insomnia over the past two weeks.

How the ISI is scored:

  • The ISI consists of 7 items, each rated on a 0–4 Likert scale
  • Total scores range from 0 to 28
  • Higher scores indicate greater insomnia severity

Severity levels:

  • 0–7: No clinically significant insomnia — Your sleep appears to be within normal range. No intervention needed, though continuing good sleep habits is always beneficial.
  • 8–14: Subthreshold insomnia — You may be experiencing some sleep difficulties that are below clinical thresholds. Monitoring and sleep hygiene improvements may be sufficient.
  • 15–21: Moderate clinical insomnia (moderate severity) — Your insomnia is clinically significant. Treatment is recommended, particularly Cognitive Behavioral Therapy for Insomnia (CBT-I).
  • 22–28: Severe clinical insomnia (severe) — Your insomnia is severe and likely causing substantial daytime impairment. Professional treatment is strongly recommended.

Clinical use and tracking progress: The ISI is widely used in clinical trials and sleep medicine practice to assess insomnia severity and track treatment response. A reduction of 8 or more points is generally considered a clinically meaningful improvement. The ISI is recommended by the American Academy of Sleep Medicine as a patient-reported outcome measure for insomnia research and clinical practice.

Psychometric properties: The ISI has demonstrated excellent internal consistency (Cronbach’s alpha = 0.74–0.91), good test-retest reliability, and strong convergent validity with sleep diary measures and polysomnography findings.

Evidence-Based Treatment Options

Insomnia is one of the most treatable sleep disorders, with several evidence-based options available:

Cognitive Behavioral Therapy for Insomnia (CBT-I) — Gold Standard:

  • CBT-I is recommended as the first-line treatment for chronic insomnia by the American College of Physicians, the American Academy of Sleep Medicine, and the European Sleep Research Society
  • It typically involves 4–8 sessions with a trained therapist and addresses the thoughts and behaviors that perpetuate insomnia
  • Components include sleep restriction therapy, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene education
  • Produces durable improvements that persist long after treatment ends, unlike medication
  • Available in-person, via telehealth, and through digital/app-based programs (e.g., CBT-I Coach, Somryst/Pear Therapeutics)

Sleep Restriction Therapy:

  • A core component of CBT-I that limits time in bed to match actual sleep time
  • Creates mild sleep deprivation that builds sleep drive and consolidates sleep
  • Gradually increases time in bed as sleep efficiency improves (target: 85%+ efficiency)
  • Can be challenging initially but is one of the most effective single-component interventions

Stimulus Control Therapy:

  • Strengthens the association between bed/bedroom and sleep
  • Rules include: go to bed only when sleepy, leave bed if awake for 15–20 minutes, use bed only for sleep and intimacy, maintain a fixed wake time, avoid napping
  • Developed by Richard Bootzin in 1972 and supported by decades of research

Medication options (always under medical supervision):

  • Melatonin receptor agonists (e.g., ramelteon) — target the circadian system with low abuse potential
  • Orexin receptor antagonists (e.g., suvorexant, lemborexant) — newer medications that block wakefulness-promoting signals
  • Short-acting benzodiazepine receptor agonists (e.g., zolpidem, eszopiclone) — effective short-term but risk of dependence
  • Low-dose doxepin — FDA-approved for sleep maintenance insomnia
  • Over-the-counter melatonin — may help with circadian timing issues; limited evidence for primary insomnia

Important note: Medication is generally recommended only for short-term use or as an adjunct to CBT-I. Long-term use of sleep medications can lead to tolerance, dependence, and rebound insomnia. CBT-I provides more lasting benefits without these risks.

10 Evidence-Based Sleep Hygiene Tips

Sleep hygiene alone is rarely sufficient to treat clinical insomnia, but these practices form the foundation of healthy sleep and complement other treatments:

  • 1. Maintain a consistent sleep schedule: Go to bed and wake up at the same time every day, including weekends. This reinforces your circadian rhythm and improves sleep quality over time. Irregular schedules are one of the most common contributors to insomnia.
  • 2. Create an optimal sleep environment: Keep your bedroom cool (65–68°F / 18–20°C), dark, and quiet. Use blackout curtains, earplugs, or a white noise machine as needed. Invest in a comfortable mattress and pillows.
  • 3. Limit screen time before bed: Avoid phones, tablets, computers, and television for at least 30–60 minutes before bedtime. Blue light from screens suppresses melatonin production and delays sleep onset. Use night mode or blue-light-blocking glasses if screens are unavoidable.
  • 4. Avoid caffeine after noon: Caffeine has a half-life of 5–7 hours, meaning half is still in your system many hours after consumption. Avoid coffee, tea, energy drinks, and chocolate in the afternoon and evening. Be aware of hidden caffeine in medications and supplements.
  • 5. Limit alcohol consumption: Although alcohol may help you fall asleep faster, it disrupts sleep architecture, reduces REM sleep, and increases nighttime awakenings. Avoid alcohol within 3–4 hours of bedtime.
  • 6. Exercise regularly, but not too late: Regular physical activity improves sleep quality and duration. Aim for at least 150 minutes of moderate exercise per week. Complete vigorous exercise at least 3–4 hours before bedtime, as exercising too close to sleep can be stimulating.
  • 7. Develop a relaxing bedtime routine: Engage in calming activities for 30–60 minutes before bed, such as reading (not on a screen), gentle stretching, meditation, deep breathing, or a warm bath. A consistent routine signals your body that it is time to wind down.
  • 8. Avoid large meals and excessive fluids before bed: Eating a heavy meal within 2–3 hours of bedtime can cause discomfort, acid reflux, and disrupted sleep. Limit fluid intake in the evening to reduce nighttime bathroom trips.
  • 9. Get natural light exposure during the day: Exposure to bright, natural light during the morning and daytime helps regulate your circadian clock and promotes better sleep at night. Aim for at least 30 minutes of outdoor light, especially in the morning.
  • 10. Reserve the bed for sleep and intimacy only: Avoid working, eating, watching TV, or scrolling your phone in bed. This strengthens the mental association between your bed and sleep, making it easier to fall asleep when you get into bed.

Frequently Asked Questions

The Insomnia Severity Index (ISI) is a brief, validated self-report questionnaire developed by Dr. Charles M. Morin and colleagues in 1993. It consists of 7 items that assess the nature, severity, and impact of insomnia over the past two weeks. The ISI evaluates difficulty falling asleep, staying asleep, and waking too early, along with sleep satisfaction, daytime impairment, noticeability to others, and worry about sleep. It is widely used in clinical practice and research as a reliable measure of insomnia severity and treatment outcomes.

ISI scores of 15 or higher indicate clinical insomnia. Specifically, scores of 15–21 represent moderate clinical insomnia, and scores of 22–28 represent severe clinical insomnia. Scores of 8–14 indicate subthreshold insomnia, meaning you may have some sleep difficulties that have not yet reached the clinical threshold. Scores of 0–7 suggest no clinically significant insomnia. These cutoffs have been validated against clinical diagnoses and are used in research and clinical practice worldwide.

The gold standard treatment for chronic insomnia is Cognitive Behavioral Therapy for Insomnia (CBT-I), which is recommended as first-line treatment by major medical organizations including the American College of Physicians. CBT-I addresses the thoughts and behaviors that perpetuate insomnia through techniques such as sleep restriction, stimulus control, cognitive restructuring, and relaxation training. It typically involves 4–8 sessions and produces lasting improvements. Medication may be used short-term or as an adjunct, but CBT-I provides more durable benefits without the risks of dependence or side effects associated with sleep medications.

Sleep medications can be helpful in the short term but are generally not recommended as a long-term solution for chronic insomnia. They can lead to tolerance (needing higher doses for the same effect), dependence, and rebound insomnia when discontinued. Current clinical guidelines recommend CBT-I as the first-line treatment, with medication considered only when CBT-I is not available, not effective, or when short-term relief is needed. If you are considering sleep medication, discuss the options, risks, and benefits with your healthcare provider. Newer medications such as orexin receptor antagonists have a more favorable safety profile than older sleeping pills.

The ISI assesses insomnia severity over the past two weeks, so retaking it every 2–4 weeks is appropriate for monitoring changes. In clinical settings, the ISI is commonly administered at each therapy session (usually weekly during CBT-I treatment) to track progress. A decrease of 8 or more points is generally considered a clinically meaningful improvement. Avoid taking it more frequently than once per week, as short-term fluctuations may not reflect true changes in your insomnia. Regular monitoring can help you and your healthcare provider assess whether your treatment is working effectively.

No. The ISI is a screening and severity measurement tool, not a diagnostic instrument. While it provides a reliable indication of insomnia severity, a formal diagnosis of insomnia disorder requires a comprehensive evaluation by a qualified healthcare provider. This evaluation typically includes a detailed sleep history, assessment of medical and psychiatric conditions that may contribute to sleep difficulties, and sometimes a sleep diary or overnight sleep study (polysomnography). The ISI is best used as a starting point for conversation with your healthcare provider or as a tool to track treatment progress over time.

Medical Disclaimer

This Insomnia Severity Index (ISI) Assessment is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The ISI is a screening tool, not a clinical diagnostic instrument. Your results should be interpreted in the context of a comprehensive assessment by a qualified healthcare professional. If you are experiencing severe insomnia or other sleep-related concerns, please consult your healthcare provider. All calculations are performed in your browser — no personal data is stored on our servers or shared with any third party.

References

  1. Morin CM. Insomnia: Psychological Assessment and Management. New York: Guilford Press; 1993.
  2. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297-307.
  3. Morin CM, Belleville G, Bélanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601-608.
  4. Buysse DJ. Insomnia. JAMA. 2013;309(7):706-716.

ISI: Morin, C.M. (1993). Insomnia: Psychological Assessment and Management. New York: Guilford Press. Validated by Bastien, Vallières, & Morin (2001).